

Summary of Studies Supporting USDA Product Licensure

Establishment Name	Diamond Animal Health, Inc.
USDA Vet Biologics Establishment Number	213
Product Code	4389.21
True Name	Bovine Rhinotracheitis-Virus Diarrhea Vaccine, Modified Live Virus, Leptospira Pomona Bacterin
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Elanco Animal Health - Diamond Animal Health, Inc. Elanco US, Inc Diamond Animal Health, Inc. Titanium 3 LP - Elanco Animal Health - Diamond Animal Health, Inc. Titanium 3 LP - Elanco US, Inc Diamond Animal Health, Inc.
Date of Compilation Summary	September 24, 2021

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

~			
Study Type	Efficacy		
Pertaining to	Bovine Virus Diarrhea Type 1		
Study Purpose	To demonstrate effectiveness against disease caused by bovine		
	virus diarrhea type 1		
Product Administration	1 dose to calves 6-8 months of age.		
Study Animals	Bovine		
Challenge Description	BVDV NY-1 Strain non-cytopathic Type 1b		
Interval observed after			
challenge			
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.		
USDA Approval Date	July 14, 1998		

Study Type	Efficacy		
Pertaining to	Bovine Virus Diarrhea Virus (BVDV) Type 2		
Study Purpose	To demonstrate effectiveness against disease caused by bovine		
	virus diarrhea type 2		
Product Administration			
Study Animals	Bovine		
Challenge Description	BVDV Type 2a strain 890		
Interval observed after			
challenge			
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.		
USDA Approval Date	July 14, 1998		

Study Type	Efficacy			
	5			
Pertaining to	Infectious Bovine Rhinotracheitis (IBR) Virus			
Study Purpose	To demonstrate effectiveness against disease caused by infectious			
	bovine rhinotracheitis virus.			
Product Administration	1 dose to calves 6-8 months of age.			
Study Animals	Bovine			
Challenge Description				
Interval observed after				
challenge				
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.			
USDA Approval Date	July 13, 1998			

Study Type	Efficacy		
Pertaining to	Leptospira pomonaa		
Study Purpose	Demonstrate efficacy against L. pomona		
Product Administration	One dose		
Study Animals	Bovine		
Challenge Description			
Interval observed after			
challenge			
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.		
USDA Approval Date	January 5, 1983		

Study Type	Efficient		
Study Type	Efficacy		
Pertaining to	Leptospira pomona		
Study Purpose	Demonstrate efficacy against L. pomona		
Product Administration	One dose		
Study Animals	Bovine		
Challenge Description			
Interval observed after			
challenge			
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. Study data, however, are no longer available.		
USDA Approval Date	March 1, 1978		

Standay True a	Cafaty		
Study Type	Safety		
Pertaining to	ALL		
Study Purpose	Demonstrate safety of product under typical use conditions		
Product Administration	One dose		
Study Animals	Bovine		
Challenge Description	NA		
Interval observed after			
challenge			
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.		
USDA Approval Date	July 13, 1998		

Study Type	Safety				
Pertaining to	ALL				
Study Purpose	To demonstrate safety in pregnant cows and calves nursing				
	pregnant cows				
Product	Two doses admini	istered	subcutaneously t	o heifers and cows, 1	
Administration		dose prior to breeding and 1 dose during pregnancy at different			
	trimesters. Heifers and cows were confirmed to be pregnant at				
	administration dur			1 0	
Study Animals	Heifers and cows-	Heifers and cows-separate groups vaccinated during each trimester.			
U U				re maintained as controls.	
Challenge Description	NA	1			
Interval observed after		observ	ved from pre-breed	ding vaccination through	
challenge				hrough 4 weeks of age.	
Results	Summary of Calv				
	(Normal calves de)	
				,	
	Trimester	Vacc	inates	Controls	
	1		208 (96%)	205/213 (96%)	
	2		313 (96%)	293/308 (95%)	
	3		205 (94%)	195/208 (94%)	
	Total		726 (96%)	693/729 (95%)	
	First Trimester (≤	93 day	vs of gestation)		
			Vaccinate	Control	
	Enrolled		209	213	
	Excluded (not re	lated	1	0	
	to vaccination)				
	Aborted or stillborn 6		6	5	
	Died at or after b	oirth	2	3	
	Second Trimester	(94-1	87 days of gestation	on)	
			Vaccinate	Control	
	Enrolled Excluded (not related		315	310	
			2	2	
	to vaccination)				
	Aborted or stillborn7Died at or after birth4		7	9	
			4	6*	
	*one death was from a set of twins; the other was normal				
	Third Trimester (188-250 days of gestation) Vaccinate Control				
				Control	
	Enrolled20Aborted or stillborn9Died at or after birth3		205	208	
			9	9*	
			3	4**	
			a set of twins; the	other was normal	
	**one dead was fr				

USDA Approval Date	March 5, 2013